VirtualScopics (VirtualScopics) Debt-to-Equity : 0.10 (As of Dec. 2015)

View and export this data going back to . Start your Free Trial

What is VirtualScopics Debt-to-Equity?

VirtualScopics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2015 was $0.11 Mil. VirtualScopics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2015 was $0.27 Mil. VirtualScopics's Total Stockholders Equity for the quarter that ended in Dec. 2015 was $3.80 Mil. VirtualScopics's debt to equity for the quarter that ended in Dec. 2015 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for VirtualScopics's Debt-to-Equity or its related term are showing as below:

VSCP's Debt-to-Equity is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 0.21
* Ranked among companies with meaningful Debt-to-Equity only.

VirtualScopics Debt-to-Equity Historical Data

The historical data trend for VirtualScopics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VirtualScopics Debt-to-Equity Chart

VirtualScopics Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Debt-to-Equity

Get a 7-Day Free Trial

0.10

VirtualScopics Quarterly Data
	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	0.09	0.10

Competitive Comparison of VirtualScopics's Debt-to-Equity

For the Medical Devices subindustry, VirtualScopics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VirtualScopics's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VirtualScopics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where VirtualScopics's Debt-to-Equity falls into.

VirtualScopics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

VirtualScopics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.108	+	0.272)	/	3.797
	=	0.10

VirtualScopics's Debt to Equity Ratio for the quarter that ended in Dec. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.108	+	0.272)	/	3.797
	=	0.10

VirtualScopics (NAS:VSCP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

VirtualScopics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of VirtualScopics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

VirtualScopics (VirtualScopics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » VirtualScopics Inc (NAS:VSCP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.virtualscopics.com

VirtualScopics Inc. is a provider of quantitative imaging for clinical trials serving the pharmaceutical, biotechnology and medical device industries. The Company has developed a software platform for analysis and modeling of both structural and functional medical images. This platform provides information about the biological activity of drugs and devices in clinical trial patients. VirtualScopics is an imaging core lab providing central reads and quantitative imaging solutions for drug and medical device clinical trials for the areas of oncology, rheumatoid arthritis, osteoarthritis, neurology, and cardiovascular studies utilizing MRI, PET, CT, Ultrasound, and X-ray imaging modalities. The Company's image-based measurement and visualization tools enable automated and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological and neurological diseases. The Company's image analysis provides a degree of accuracy and reproducibility that cannot be duplicated by manual techniques. The Company's quantitative imaging replaces subjective evaluation. It has developed a suite of patented semi-automated tools for the identification and measurement of carotid plaques. Evaluating diseases such as multiple sclerosis (MS), epilepsy, and Alzheimer's requires the identification and measurement of neurological structures and lesions. The Company's competition is largely comprised of a limited number of university research centers that are working on developing the next generation of image analysis tools. The Company's main customers are Novartis, Merck Serono and Amgen. The Company's main competitors are clinical research organizations (CROs) providing clinical trial services to pharmaceutical companies. Healthcare in the United States is heavily regulated by the federal government, and by state and local governments.

Executives

Robert G Klimasewski	director	35 VANTAGE POINT DRIVE, ROCHESTER NY 14624
Molly Henderson	officer: Chief Business/Financial Off.	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
David Rubin	director	C/O MERCK GLOBAL HEALTH INNOVATION FUND, ONE MERCK DRIVE, WHITEHOUSE STATION NJ 08889
Sidney R Knafel	director	810 SEVENTH AVENUE, NEW YORK NY 10019
Warren D Bagatelle	director	FUELCELL ENERGY, INC., 3 GREAT PASTURE ROAD, DANBURY CT 06813-1305

VirtualScopics (VirtualScopics) Headlines

No Headlines